{"transactions":[{"id":700528,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27712,"kind":"person","name":"Disbrow Joshua R.","position":1,"cik":"0001566240","reported_name":"Disbrow Joshua R.","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-30T20:34:20.000Z","date":"2026-07-28","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted stock, which vest as follows: 1/3 on July 28, 2027, with the remaining restricted stock vesting in 8 equal quarterly installments beginning October 28, 2027."}],"balance_after":237203,"source":{"system":"sec-edgar","filing":"0001437749-26-025083","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000143774926025083/rdgdoc.xml","form_type":"4"}},{"id":700527,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27711,"kind":"person","name":"PYSZCZYMUKA GREG","position":1,"cik":"0001952920","reported_name":"PYSZCZYMUKA GREG","relationship":{"officer":true,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-07-30T20:34:01.000Z","date":"2026-07-28","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted stock, which vest as follows: 1/3 on July 28, 2027, with the remaining restricted stock vesting in 8 equal quarterly installments beginning October 28, 2027."}],"balance_after":56102,"source":{"system":"sec-edgar","filing":"0001437749-26-025082","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000143774926025082/rdgdoc.xml","form_type":"4"}},{"id":700526,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27710,"kind":"person","name":"Disbrow Jarrett","position":1,"cik":"0001640724","reported_name":"Disbrow Jarrett","relationship":{"officer":true,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2026-07-30T20:33:43.000Z","date":"2026-07-28","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted stock, which vest as follows: 1/3 on July 28, 2027, with the remaining restricted stock vesting in 8 equal quarterly installments beginning October 28, 2027."}],"balance_after":76568,"source":{"system":"sec-edgar","filing":"0001437749-26-025081","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000143774926025081/rdgdoc.xml","form_type":"4"}},{"id":700622,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27752,"kind":"person","name":"Selhorn Ryan J","position":1,"cik":"0001670673","reported_name":"Selhorn Ryan J","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-07-30T20:33:22.000Z","date":"2026-07-28","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted stock, which vest as follows: 1/3 on July 28, 2027, with the remaining restricted stock vesting in 8 equal quarterly installments beginning October 28, 2027."}],"balance_after":74743,"source":{"system":"sec-edgar","filing":"0001437749-26-025080","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1670673/000143774926025080/rdgdoc.xml","form_type":"4"}},{"id":700558,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27727,"kind":"person","name":"LIU VIVIAN H","position":1,"cik":"0001203467","reported_name":"LIU VIVIAN H","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-07-30T20:32:12.000Z","date":"2026-07-28","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted stock, which vest on July 28, 2027."}],"balance_after":29825,"source":{"system":"sec-edgar","filing":"0001437749-26-025078","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1203467/000143774926025078/rdgdoc.xml","form_type":"4"}},{"id":700525,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":22200,"kind":"person","name":"JAIN ABHINAV","position":1,"cik":"0001981291","reported_name":"JAIN ABHINAV","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-07-30T20:31:51.000Z","date":"2026-07-28","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted stock, which vest on July 28, 2027."}],"balance_after":29500,"source":{"system":"sec-edgar","filing":"0001437749-26-025077","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000143774926025077/rdgdoc.xml","form_type":"4"}},{"id":700524,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-07-30T20:31:32.000Z","date":"2026-07-28","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted stock, which vest on July 28, 2027."}],"balance_after":31152,"source":{"system":"sec-edgar","filing":"0001437749-26-025076","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000143774926025076/rdgdoc.xml","form_type":"4"}},{"id":700523,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27708,"kind":"person","name":"Donofrio John Jr.","position":1,"cik":"0001679841","reported_name":"Donofrio John Jr.","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-07-30T20:31:10.000Z","date":"2026-07-28","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted stock, which vest on July 28, 2027."}],"balance_after":23762,"source":{"system":"sec-edgar","filing":"0001437749-26-025075","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000143774926025075/rdgdoc.xml","form_type":"4"}},{"id":1015760,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true}}],"security":"Common Shares","published_at":"2025-10-20T19:56:29.000Z","date":"2020-12-30","kind":"sale","planned":false,"acquired":false,"shares":209,"price":6.01,"value":1256.09,"ownership":{"direct":false,"nature":"Alpha Venture Capital Parner, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Person's purchase and sale of AYTU common shares (the \"Shares\") reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 209 Shares sold on December 30, 2020, with the Reporting Person's purchase of 10,000 Shares on November 18, 2020. After taking into consideration the Issuer's 10:1 reverse stock split on December 10, 2020, the price for the November 18, 2020, purchase was $9.23 per share, or a total purchase price of $1,929.07 for 209 Shares.  The total sale price of 209 Shares on December 30, 2020, was $1,256.09.  THE REPORTING PERSON DID NOT REALIZE ANY PROFIT IN CONNECTION WITH THE SHORT-SWING PURCHASE AND SALE."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000912282-25-001096","document":"form5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091228225001096/form5.xml","form_type":"5"}},{"id":1015759,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true}}],"security":"Common Shares","published_at":"2025-10-20T19:56:29.000Z","date":"2020-11-18","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":0.923,"value":9230.0,"ownership":{"direct":false,"nature":"Alpha Venture Capital Management, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Person's purchase and sale of AYTU common shares (the \"Shares\") reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 209 Shares sold on December 30, 2020, with the Reporting Person's purchase of 10,000 Shares on November 18, 2020. After taking into consideration the Issuer's 10:1 reverse stock split on December 10, 2020, the price for the November 18, 2020, purchase was $9.23 per share, or a total purchase price of $1,929.07 for 209 Shares.  The total sale price of 209 Shares on December 30, 2020, was $1,256.09.  THE REPORTING PERSON DID NOT REALIZE ANY PROFIT IN CONNECTION WITH THE SHORT-SWING PURCHASE AND SALE."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents total Shares held following stock splits on June 30, 2016 (12:1), August 25, 2017 (20:1), August 13, 2018 (20:1), December 10, 2020 (10:1) and January 6, 2023 (20:1)."}],"balance_after":50,"source":{"system":"sec-edgar","filing":"0000912282-25-001096","document":"form5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091228225001096/form5.xml","form_type":"5"}},{"id":1021997,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27711,"kind":"person","name":"PYSZCZYMUKA GREG","position":1,"cik":"0001952920","reported_name":"PYSZCZYMUKA GREG","relationship":{"officer":true,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-10-07T20:16:28.000Z","date":"2025-10-03","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted stock, which vest as follows: 1/3 on October 3, 2026, with the remaining restricted stock vesting in 8 equal quarterly installments beginning January 3, 2027."}],"balance_after":36102,"source":{"system":"sec-edgar","filing":"0001437749-25-030650","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000143774925030650/rdgdoc.xml","form_type":"4"}},{"id":1021996,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27710,"kind":"person","name":"Disbrow Jarrett","position":1,"cik":"0001640724","reported_name":"Disbrow Jarrett","relationship":{"officer":true,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2025-10-07T20:15:04.000Z","date":"2025-10-03","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Grant of restricted stock, which vest as follows: 1/3 on October 3, 2026, with the remaining restricted stock vesting in 8 equal quarterly installments beginning January 3, 2027."}],"balance_after":61568,"source":{"system":"sec-edgar","filing":"0001437749-25-030648","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000143774925030648/rdgdoc.xml","form_type":"4"}},{"id":1021995,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27710,"kind":"person","name":"Disbrow Jarrett","position":1,"cik":"0001640724","reported_name":"Disbrow Jarrett","relationship":{"officer":true,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2025-10-07T20:15:04.000Z","date":"2025-10-03","kind":"grant","planned":false,"acquired":true,"shares":19606,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person was granted fully vested restricted stock in lieu of cash in satisfaction of their annual bonus."}],"balance_after":49068,"source":{"system":"sec-edgar","filing":"0001437749-25-030648","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000143774925030648/rdgdoc.xml","form_type":"4"}},{"id":1022211,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27752,"kind":"person","name":"Selhorn Ryan J","position":1,"cik":"0001670673","reported_name":"Selhorn Ryan J","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-10-07T20:12:18.000Z","date":"2025-10-03","kind":"grant","planned":false,"acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Grant of restricted stock, which vest as follows: 1/3 on October 3, 2026, with the remaining restricted stock vesting in 8 equal quarterly installments beginning January 3, 2027."}],"balance_after":49743,"source":{"system":"sec-edgar","filing":"0001437749-25-030645","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1670673/000143774925030645/rdgdoc.xml","form_type":"4"}},{"id":1022210,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27752,"kind":"person","name":"Selhorn Ryan J","position":1,"cik":"0001670673","reported_name":"Selhorn Ryan J","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-10-07T20:12:18.000Z","date":"2025-10-03","kind":"grant","planned":false,"acquired":true,"shares":16243,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person was granted fully vested restricted stock in lieu of cash in satisfaction of their annual bonus."}],"balance_after":32243,"source":{"system":"sec-edgar","filing":"0001437749-25-030645","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1670673/000143774925030645/rdgdoc.xml","form_type":"4"}},{"id":1021994,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27712,"kind":"person","name":"Disbrow Joshua R.","position":1,"cik":"0001566240","reported_name":"Disbrow Joshua R.","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-10-07T20:11:20.000Z","date":"2025-10-03","kind":"grant","planned":false,"acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Grant of restricted stock, which vest as follows: 1/3 on October 3, 2026, with the remaining restricted stock vesting in 8 equal quarterly installments beginning January 3, 2027."}],"balance_after":207203,"source":{"system":"sec-edgar","filing":"0001437749-25-030642","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000143774925030642/rdgdoc.xml","form_type":"4"}},{"id":1021993,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27712,"kind":"person","name":"Disbrow Joshua R.","position":1,"cik":"0001566240","reported_name":"Disbrow Joshua R.","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-10-07T20:11:20.000Z","date":"2025-10-03","kind":"grant","planned":false,"acquired":true,"shares":31446,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person was granted fully vested restricted stock in lieu of cash in satisfaction of their annual bonus."}],"balance_after":184703,"source":{"system":"sec-edgar","filing":"0001437749-25-030642","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000143774925030642/rdgdoc.xml","form_type":"4"}},{"id":1022028,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27727,"kind":"person","name":"LIU VIVIAN H","position":1,"cik":"0001203467","reported_name":"LIU VIVIAN H","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-10-07T20:10:29.000Z","date":"2025-10-03","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted stock, which vest on October 3, 2026."}],"balance_after":19825,"source":{"system":"sec-edgar","filing":"0001437749-25-030639","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1203467/000143774925030639/rdgdoc.xml","form_type":"4"}},{"id":1021992,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":22200,"kind":"person","name":"JAIN ABHINAV","position":1,"cik":"0001981291","reported_name":"JAIN ABHINAV","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-10-07T20:09:15.000Z","date":"2025-10-03","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted stock, which vest on October 3, 2026."}],"balance_after":19500,"source":{"system":"sec-edgar","filing":"0001437749-25-030636","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000143774925030636/rdgdoc.xml","form_type":"4"}},{"id":1021991,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-10-07T20:08:25.000Z","date":"2025-10-03","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted stock, which vest on October 3, 2026."}],"balance_after":20440,"source":{"system":"sec-edgar","filing":"0001437749-25-030634","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000143774925030634/rdgdoc.xml","form_type":"4"}},{"id":1021990,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27708,"kind":"person","name":"Donofrio John Jr.","position":1,"cik":"0001679841","reported_name":"Donofrio John Jr.","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-10-07T20:06:59.000Z","date":"2025-10-03","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted stock, which vest on October 3, 2026."}],"balance_after":13762,"source":{"system":"sec-edgar","filing":"0001437749-25-030632","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000143774925030632/rdgdoc.xml","form_type":"4"}},{"id":1116045,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27710,"kind":"person","name":"Disbrow Jarrett","position":1,"cik":"0001640724","reported_name":"Disbrow Jarrett","relationship":{"officer":true,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2025-06-10T19:06:06.000Z","date":"2025-06-09","kind":"purchase","planned":false,"acquired":true,"shares":16666,"price":1.5,"value":24999.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Purchased pursuant to the Issuer's registered offering more particularly described on the Registration Statement on Form S-1, as amended, filed by the Issuer on June 2, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Total reflects 1-to-20 reverse stock split effected by the Issuer on January 6, 2023."}],"balance_after":29462,"source":{"system":"sec-edgar","filing":"0001437749-25-019958","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000143774925019958/rdgdoc.xml","form_type":"4"}},{"id":1116044,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27712,"kind":"person","name":"Disbrow Joshua R.","position":1,"cik":"0001566240","reported_name":"Disbrow Joshua R.","relationship":{"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-06-10T19:04:30.000Z","date":"2025-06-09","kind":"purchase","planned":false,"acquired":true,"shares":66666,"price":1.5,"value":99999.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Purchased pursuant to the Issuer's registered offering more particularly described on the Registration Statement on Form S-1, as amended, filed by the Issuer on June 2, 2025."}],"balance_after":153257,"source":{"system":"sec-edgar","filing":"0001437749-25-019956","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000143774925019956/rdgdoc.xml","form_type":"4"}},{"id":1118009,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":60000,"kind":"organization","name":"Nantahala Capital Management, LLC","position":1,"cik":"0001472322","reported_name":"Nantahala Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":60001,"kind":"person","name":"Harkey Wilmot B.","position":2,"cik":"0001775952","reported_name":"Harkey Wilmot B.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":60002,"kind":"person","name":"Mack Daniel","position":3,"cik":"0001775831","reported_name":"Mack Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Prefunded Warrants","published_at":"2025-06-09T16:31:42.000Z","date":"2025-06-06","kind":"purchase","planned":false,"acquired":true,"shares":4000000,"price":1.4999,"value":5999600.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to certain limits on beneficial ownership, the Prefunded Warrants may be exercised to purchase Issuer Common Stock at an exercise price of $0.0001 per share. The Prefunded Warrants do not expire until exercised in full."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Subject to certain limits on beneficial ownership, the Prefunded Warrants may be exercised to purchase Issuer Common Stock at an exercise price of $0.0001 per share. The Prefunded Warrants do not expire until exercised in full."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Nantahala Capital Management, LLC (\"NCM\"), an investment adviser to certain private funds and managed accounts (the \"NCM Investors\") that hold the Aytu BioPharma, Inc (\"Issuer\") securities disclosed in this Form 4, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein."}],"balance_after":4815217,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":4000000},"source":{"system":"sec-edgar","filing":"0001104659-25-057852","document":"tm2517486-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1775831/000110465925057852/tm2517486-1_4seq1.xml","form_type":"4"}},{"id":1187765,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27711,"kind":"person","name":"PYSZCZYMUKA GREG","position":1,"cik":"0001952920","reported_name":"PYSZCZYMUKA GREG","relationship":{"officer":true,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2025-03-31T20:34:24.000Z","date":"2025-03-31","kind":"exercise","planned":false,"acquired":false,"shares":209,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs were granted on March 31, 2022, and vest quarterly beginning March 31, 2023 and ending March 31, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs were granted on March 31, 2022, and vest quarterly beginning March 31, 2023 and ending March 31, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs were granted on March 31, 2022, and vest quarterly beginning March 31, 2023 and ending March 31, 2025."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":209},"source":{"system":"sec-edgar","filing":"0001437749-25-010224","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000143774925010224/rdgdoc.xml","form_type":"4"}},{"id":1187764,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27711,"kind":"person","name":"PYSZCZYMUKA GREG","position":1,"cik":"0001952920","reported_name":"PYSZCZYMUKA GREG","relationship":{"officer":true,"officer_title":"Chief Commercial Officer"}}],"security":"Common Shares","published_at":"2025-03-31T20:34:24.000Z","date":"2025-03-31","kind":"exercise","planned":false,"acquired":true,"shares":209,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs were granted on March 31, 2022, and vest quarterly beginning March 31, 2023 and ending March 31, 2025."}],"balance_after":23602,"source":{"system":"sec-edgar","filing":"0001437749-25-010224","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000143774925010224/rdgdoc.xml","form_type":"4"}},{"id":1235809,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27752,"kind":"person","name":"Selhorn Ryan J","position":1,"cik":"0001670673","reported_name":"Selhorn Ryan J","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2025-03-04T00:22:47.000Z","date":"2025-02-05","kind":"exercise","planned":false,"acquired":false,"shares":105,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units (RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted February 5, 2022, vesting quarterly beginning February 5, 2023, and ending February 5, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Restricted stock units (RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted February 5, 2022, vesting quarterly beginning February 5, 2023, and ending February 5, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Restricted stock units (RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted February 5, 2022, vesting quarterly beginning February 5, 2023, and ending February 5, 2025."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":105},"source":{"system":"sec-edgar","filing":"0000912282-25-000223","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1670673/000091228225000223/form4.xml","form_type":"4"}},{"id":1235808,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27752,"kind":"person","name":"Selhorn Ryan J","position":1,"cik":"0001670673","reported_name":"Selhorn Ryan J","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Shares","published_at":"2025-03-04T00:22:47.000Z","date":"2025-02-05","kind":"exercise","planned":false,"acquired":true,"shares":105,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units (RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted February 5, 2022, vesting quarterly beginning February 5, 2023, and ending February 5, 2025."}],"balance_after":16000,"source":{"system":"sec-edgar","filing":"0000912282-25-000223","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1670673/000091228225000223/form4.xml","form_type":"4"}},{"id":1235328,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27712,"kind":"person","name":"Disbrow Joshua R.","position":1,"cik":"0001566240","reported_name":"Disbrow Joshua R.","relationship":{"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-03-03T18:35:04.000Z","date":"2025-02-28","kind":"purchase","planned":false,"acquired":true,"shares":15000,"price":1.3,"value":19500.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On February 28, 2025, Joshua R. Disbrow, purchased a total of 15,000 shares of common stock in multiple open market transaction at prices per share ranging from $1.29 to $1.30, with a weighted average price of approximately $1.30 per share. Mr. Disbrow undertakes to provide to AYTU BIOPHARMA, INC., any security holder of AYTU BIOPHARMA, INC., or the staff of the United States Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 28, 2025, Joshua R. Disbrow, purchased a total of 15,000 shares of common stock in multiple open market transaction at prices per share ranging from $1.29 to $1.30, with a weighted average price of approximately $1.30 per share. Mr. Disbrow undertakes to provide to AYTU BIOPHARMA, INC., any security holder of AYTU BIOPHARMA, INC., or the staff of the United States Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."}],"balance_after":86591,"source":{"system":"sec-edgar","filing":"0001437749-25-005873","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000143774925005873/rdgdoc.xml","form_type":"4"}},{"id":1318365,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27711,"kind":"person","name":"PYSZCZYMUKA GREG","position":1,"cik":"0001952920","reported_name":"PYSZCZYMUKA GREG","relationship":{"officer":true,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2025-01-02T22:02:47.000Z","date":"2024-12-31","kind":"exercise","planned":false,"acquired":false,"shares":208,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted on March 31, 2022, and vest quarterly beginning March 31, 2023 and ending March 31, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted on March 31, 2022, and vest quarterly beginning March 31, 2023 and ending March 31, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted on March 31, 2022, and vest quarterly beginning March 31, 2023 and ending March 31, 2025."}],"balance_after":209,"derivative":{"underlying":"Common Shares","underlying_shares":208},"source":{"system":"sec-edgar","filing":"0000912282-25-000018","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091228225000018/form4.xml","form_type":"4"}},{"id":1318364,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27711,"kind":"person","name":"PYSZCZYMUKA GREG","position":1,"cik":"0001952920","reported_name":"PYSZCZYMUKA GREG","relationship":{"officer":true,"officer_title":"Chief Commercial Officer"}}],"security":"Common Shares","published_at":"2025-01-02T22:02:47.000Z","date":"2024-12-31","kind":"exercise","planned":false,"acquired":true,"shares":208,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted on March 31, 2022, and vest quarterly beginning March 31, 2023 and ending March 31, 2025."}],"balance_after":23393,"source":{"system":"sec-edgar","filing":"0000912282-25-000018","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091228225000018/form4.xml","form_type":"4"}},{"id":1366562,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27752,"kind":"person","name":"Selhorn Ryan J","position":1,"cik":"0001670673","reported_name":"Selhorn Ryan J","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Shares","published_at":"2024-11-13T21:10:22.000Z","date":"2024-11-11","kind":"grant","planned":false,"acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of restricted stock which vest as follows:  One-third on November 11, 2025; 1/12th of the original grant quarterly thereafter through November 11, 2027."}],"balance_after":15895,"source":{"system":"sec-edgar","filing":"0000912282-24-000798","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1670673/000091228224000798/form4.xml","form_type":"4"}},{"id":1371041,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true}}],"security":"Common Shares","published_at":"2024-11-09T01:44:23.000Z","date":"2024-11-06","kind":"grant","planned":false,"acquired":true,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted shares, which vest on the earlier of November 6, 2025, or at the Issuer's next annual stockholder meeting."}],"balance_after":10440,"source":{"system":"sec-edgar","filing":"0000912282-24-000764","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091228224000764/form4.xml","form_type":"4"}},{"id":1371040,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27708,"kind":"person","name":"Donofrio John Jr.","position":1,"cik":"0001679841","reported_name":"Donofrio John Jr.","relationship":{"director":true}}],"security":"Common Shares","published_at":"2024-11-09T01:34:59.000Z","date":"2024-11-06","kind":"grant","planned":false,"acquired":true,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Grant of restricted shares, which vest on the earlier of November 6, 2025, or at the Issuer's next annual stockholder meeting."},{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted shares, which vest on the earlier of November 6, 2025, or at the Issuer's next annual stockholder meeting."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Grant of restricted shares, which vest on the earlier of November 6, 2025, or at the Issuer's next annual stockholder meeting."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Grant of restricted shares, which vest on the earlier of November 6, 2025, or at the Issuer's next annual stockholder meeting."}],"balance_after":3762,"source":{"system":"sec-edgar","filing":"0000912282-24-000762","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091228224000762/form4.xml","form_type":"4"}},{"id":1371039,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":22200,"kind":"person","name":"JAIN ABHINAV","position":1,"cik":"0001981291","reported_name":"JAIN ABHINAV","relationship":{"director":true}}],"security":"Common Shares","published_at":"2024-11-09T01:27:08.000Z","date":"2024-11-06","kind":"grant","planned":false,"acquired":true,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted shares, which vest on the earlier of November 6, 2025, or at the Issuer's next annual stockholder meeting."}],"balance_after":9500,"source":{"system":"sec-edgar","filing":"0000912282-24-000760","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091228224000760/form4.xml","form_type":"4"}},{"id":1371038,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27712,"kind":"person","name":"Disbrow Joshua R.","position":1,"cik":"0001566240","reported_name":"Disbrow Joshua R.","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2024-11-09T00:55:50.000Z","date":"2024-11-06","kind":"grant","planned":false,"acquired":true,"shares":38000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest as follows:  1/3 on November 6, 2025, with the remaining options vesting in 24 equal monthly installments beginning December 6, 2025."}],"balance_after":38000,"derivative":{"exercise_price":1.84,"expiration_date":"2034-11-06","underlying":"Common Shares","underlying_shares":38000},"source":{"system":"sec-edgar","filing":"0000912282-24-000758","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091228224000758/form4.xml","form_type":"4"}},{"id":1371037,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27710,"kind":"person","name":"Disbrow Jarrett","position":1,"cik":"0001640724","reported_name":"Disbrow Jarrett","relationship":{"officer":true,"officer_title":"Chief Business Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2024-11-09T00:49:42.000Z","date":"2024-11-06","kind":"grant","planned":false,"acquired":true,"shares":7000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest as follows:  1/3 on November 6, 2025, with the remaining options vesting in 24 equal monthly installments beginning December 6, 2025."}],"balance_after":7000,"derivative":{"exercise_price":1.84,"expiration_date":"2034-11-06","underlying":"Common Shares","underlying_shares":7000},"source":{"system":"sec-edgar","filing":"0000912282-24-000756","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091228224000756/form4.xml","form_type":"4"}},{"id":1371172,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27727,"kind":"person","name":"LIU VIVIAN H","position":1,"cik":"0001203467","reported_name":"LIU VIVIAN H","relationship":{"director":true}}],"security":"Common Shares","published_at":"2024-11-09T00:37:55.000Z","date":"2024-11-06","kind":"grant","planned":false,"acquired":true,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted shares, which vest on the earlier of November 6, 2025, or at the Issuer's next annual stockholder meeting."}],"balance_after":9825,"source":{"system":"sec-edgar","filing":"0000912282-24-000754","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1203467/000091228224000754/form4.xml","form_type":"4"}},{"id":1371170,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27727,"kind":"person","name":"LIU VIVIAN H","position":1,"cik":"0001203467","reported_name":"LIU VIVIAN H","relationship":{"director":true}}],"security":"Common Shares","published_at":"2024-11-09T00:32:43.000Z","date":"2023-08-11","kind":"grant","planned":false,"acquired":true,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted shares, which vest as follows:  1/3 on August 11, 2024, with the remaining restricted shares vesting in eight equal installments every three months beginning November 11, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects 1-for-20 reverse stock split effected by the Issuer on January 6, 2023."}],"balance_after":8325,"source":{"system":"sec-edgar","filing":"0000912282-24-000752","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1203467/000091228224000752/form4.xml","form_type":"4/A","original_submission_date":"2023-08-15"}},{"id":1371036,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27711,"kind":"person","name":"PYSZCZYMUKA GREG","position":1,"cik":"0001952920","reported_name":"PYSZCZYMUKA GREG","relationship":{"officer":true,"officer_title":"Chief Commercial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2024-11-09T00:23:40.000Z","date":"2024-11-06","kind":"grant","planned":false,"acquired":true,"shares":7000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest as follows:  1/3 on November 6, 2025, with the remaining options vesting in 24 equal monthly installments beginning December 6, 2025."}],"balance_after":7000,"derivative":{"exercise_price":1.84,"expiration_date":"2034-11-06","underlying":"Common Shares","underlying_shares":7000},"source":{"system":"sec-edgar","filing":"0000912282-24-000750","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091228224000750/form4.xml","form_type":"4"}},{"id":1393838,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27711,"kind":"person","name":"PYSZCZYMUKA GREG","position":1,"cik":"0001952920","reported_name":"PYSZCZYMUKA GREG","relationship":{"officer":true,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2024-10-02T21:18:57.000Z","date":"2024-09-30","kind":"exercise","planned":false,"acquired":false,"shares":209,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted on March 31, 2022, and vest quarterly beginning March 31, 2023 and ending March 31, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted on March 31, 2022, and vest quarterly beginning March 31, 2023 and ending March 31, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted on March 31, 2022, and vest quarterly beginning March 31, 2023 and ending March 31, 2025."}],"balance_after":417,"derivative":{"underlying":"Common Shares","underlying_shares":209},"source":{"system":"sec-edgar","filing":"0000912282-24-000682","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091228224000682/form4.xml","form_type":"4"}},{"id":1393837,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27711,"kind":"person","name":"PYSZCZYMUKA GREG","position":1,"cik":"0001952920","reported_name":"PYSZCZYMUKA GREG","relationship":{"officer":true,"officer_title":"Chief Commercial Officer"}}],"security":"Common Shares","published_at":"2024-10-02T21:18:57.000Z","date":"2024-09-30","kind":"exercise","planned":false,"acquired":true,"shares":209,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted on March 31, 2022, and vest quarterly beginning March 31, 2023 and ending March 31, 2025."}],"balance_after":23185,"source":{"system":"sec-edgar","filing":"0000912282-24-000682","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091228224000682/form4.xml","form_type":"4"}},{"id":1462265,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27711,"kind":"person","name":"PYSZCZYMUKA GREG","position":1,"cik":"0001952920","reported_name":"PYSZCZYMUKA GREG","relationship":{"officer":true,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2024-07-02T21:20:16.000Z","date":"2024-06-30","kind":"exercise","planned":false,"acquired":false,"shares":208,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted on March 31, 2022, and vest quarterly beginning March 31, 2023 and ending March 31, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted on March 31, 2022, and vest quarterly beginning March 31, 2023 and ending March 31, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted on March 31, 2022, and vest quarterly beginning March 31, 2023 and ending March 31, 2025."}],"balance_after":626,"derivative":{"underlying":"Common Shares","underlying_shares":208},"source":{"system":"sec-edgar","filing":"0000912282-24-000527","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091228224000527/form4.xml","form_type":"4"}},{"id":1462264,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27711,"kind":"person","name":"PYSZCZYMUKA GREG","position":1,"cik":"0001952920","reported_name":"PYSZCZYMUKA GREG","relationship":{"officer":true,"officer_title":"Chief Commercial Officer"}}],"security":"Common Shares","published_at":"2024-07-02T21:20:16.000Z","date":"2024-06-30","kind":"exercise","planned":false,"acquired":true,"shares":208,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted on March 31, 2022, and vest quarterly beginning March 31, 2023 and ending March 31, 2025."}],"balance_after":22976,"source":{"system":"sec-edgar","filing":"0000912282-24-000527","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091228224000527/form4.xml","form_type":"4"}},{"id":1475444,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":60000,"kind":"organization","name":"Nantahala Capital Management, LLC","position":1,"cik":"0001472322","reported_name":"Nantahala Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":60001,"kind":"person","name":"Harkey Wilmot B.","position":2,"cik":"0001775952","reported_name":"Harkey Wilmot B.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":60002,"kind":"person","name":"Mack Daniel","position":3,"cik":"0001775831","reported_name":"Mack Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Exchange Warrants","published_at":"2024-06-18T17:09:09.000Z","date":"2024-06-14","kind":"other","planned":false,"acquired":true,"shares":815217,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Subject to certain limits on beneficial ownership, the Exchange Warrants may be exercised to purchase Issuer Common Stock at an exercise price of $0.0001 per share. The Exchange Warrants do not expire until exercised in full."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Subject to certain limits on beneficial ownership, the Exchange Warrants may be exercised to purchase Issuer Common Stock at an exercise price of $0.0001 per share. The Exchange Warrants do not expire until exercised in full."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Nantahala Capital Management, LLC (\"NCM\"), an investment adviser to certain private funds and managed accounts (the \"NCM Investors\") that hold the Aytu BioPharma, Inc (\"Issuer\") securities disclosed in this Form 4, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein."}],"balance_after":815217,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":815217},"source":{"system":"sec-edgar","filing":"0001104659-24-072893","document":"tm2417545-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1775831/000110465924072893/tm2417545-2_4seq1.xml","form_type":"4"}},{"id":1475443,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":60000,"kind":"organization","name":"Nantahala Capital Management, LLC","position":1,"cik":"0001472322","reported_name":"Nantahala Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":60001,"kind":"person","name":"Harkey Wilmot B.","position":2,"cik":"0001775952","reported_name":"Harkey Wilmot B.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":60002,"kind":"person","name":"Mack Daniel","position":3,"cik":"0001775831","reported_name":"Mack Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Tranche B Warrant","published_at":"2024-06-18T17:09:09.000Z","date":"2024-06-14","kind":"other","planned":false,"acquired":false,"shares":815217,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Tranche B Warrants may be exercised for either shares of Common Stock or Exchange Warrants. Subject to certain limits on beneficial ownership, the Tranche B Warrants are exercisable at a price of $1.59 per share (or $1.5899 per Exchange Warrant). The Tranche B Warrants will expire upon the earlier of (x) five years after the date of issuance, and (y) 30 days following the Issuer's achievement of consolidated trailing twelve-month adjusted EBITDA of $12 million."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Tranche B Warrants may be exercised for either shares of Common Stock or Exchange Warrants. Subject to certain limits on beneficial ownership, the Tranche B Warrants are exercisable at a price of $1.59 per share (or $1.5899 per Exchange Warrant). The Tranche B Warrants will expire upon the earlier of (x) five years after the date of issuance, and (y) 30 days following the Issuer's achievement of consolidated trailing twelve-month adjusted EBITDA of $12 million."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Tranche B Warrants may be exercised for either shares of Common Stock or Exchange Warrants. Subject to certain limits on beneficial ownership, the Tranche B Warrants are exercisable at a price of $1.59 per share (or $1.5899 per Exchange Warrant). The Tranche B Warrants will expire upon the earlier of (x) five years after the date of issuance, and (y) 30 days following the Issuer's achievement of consolidated trailing twelve-month adjusted EBITDA of $12 million."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Tranche B Warrants may be exercised for either shares of Common Stock or Exchange Warrants. Subject to certain limits on beneficial ownership, the Tranche B Warrants are exercisable at a price of $1.59 per share (or $1.5899 per Exchange Warrant). The Tranche B Warrants will expire upon the earlier of (x) five years after the date of issuance, and (y) 30 days following the Issuer's achievement of consolidated trailing twelve-month adjusted EBITDA of $12 million."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Nantahala Capital Management, LLC (\"NCM\"), an investment adviser to certain private funds and managed accounts (the \"NCM Investors\") that hold the Aytu BioPharma, Inc (\"Issuer\") securities disclosed in this Form 4, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"exercise_price":1.5899,"underlying":"Common Stock","underlying_shares":815217},"source":{"system":"sec-edgar","filing":"0001104659-24-072893","document":"tm2417545-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1775831/000110465924072893/tm2417545-2_4seq1.xml","form_type":"4"}},{"id":1552872,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27711,"kind":"person","name":"PYSZCZYMUKA GREG","position":1,"cik":"0001952920","reported_name":"PYSZCZYMUKA GREG","relationship":{"officer":true,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2024-04-02T20:44:18.000Z","date":"2024-03-31","kind":"exercise","planned":false,"acquired":false,"shares":208,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted on March 31, 2022, and vest quarterly beginning March 31, 2023 and ending March 31, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted on March 31, 2022, and vest quarterly beginning March 31, 2023 and ending March 31, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted on March 31, 2022, and vest quarterly beginning March 31, 2023 and ending March 31, 2025."}],"balance_after":834,"derivative":{"underlying":"Common Shares","underlying_shares":208},"source":{"system":"sec-edgar","filing":"0000912282-24-000340","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091228224000340/form4.xml","form_type":"4"}},{"id":1552871,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27711,"kind":"person","name":"PYSZCZYMUKA GREG","position":1,"cik":"0001952920","reported_name":"PYSZCZYMUKA GREG","relationship":{"officer":true,"officer_title":"Chief Commercial Officer"}}],"security":"Common Shares","published_at":"2024-04-02T20:44:18.000Z","date":"2024-03-31","kind":"exercise","planned":false,"acquired":true,"shares":208,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted on March 31, 2022, and vest quarterly beginning March 31, 2023 and ending March 31, 2025."}],"balance_after":22768,"source":{"system":"sec-edgar","filing":"0000912282-24-000340","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091228224000340/form4.xml","form_type":"4"}},{"id":1696127,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27711,"kind":"person","name":"PYSZCZYMUKA GREG","position":1,"cik":"0001952920","reported_name":"PYSZCZYMUKA GREG","relationship":{"officer":true,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2024-01-02T21:37:59.000Z","date":"2023-12-31","kind":"exercise","planned":false,"acquired":false,"shares":209,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted on March 31, 2022, and vest as follows:  One-third on March 31, 2023; 1/12th of the original grant quarterly thereafter through March 31, 2025.  Settlement of vested RSUs will occur as soon as practicable following vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted on March 31, 2022, and vest as follows:  One-third on March 31, 2023; 1/12th of the original grant quarterly thereafter through March 31, 2025.  Settlement of vested RSUs will occur as soon as practicable following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted on March 31, 2022, and vest as follows:  One-third on March 31, 2023; 1/12th of the original grant quarterly thereafter through March 31, 2025.  Settlement of vested RSUs will occur as soon as practicable following vesting."}],"balance_after":1042,"derivative":{"underlying":"Common Shares","underlying_shares":209},"source":{"system":"sec-edgar","filing":"0000912282-24-000006","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091228224000006/form4.xml","form_type":"4"}},{"id":1696126,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27711,"kind":"person","name":"PYSZCZYMUKA GREG","position":1,"cik":"0001952920","reported_name":"PYSZCZYMUKA GREG","relationship":{"officer":true,"officer_title":"Chief Commercial Officer"}}],"security":"Common Shares","published_at":"2024-01-02T21:37:59.000Z","date":"2023-12-31","kind":"exercise","planned":false,"acquired":true,"shares":209,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted on March 31, 2022, and vest as follows:  One-third on March 31, 2023; 1/12th of the original grant quarterly thereafter through March 31, 2025.  Settlement of vested RSUs will occur as soon as practicable following vesting."}],"balance_after":22560,"source":{"system":"sec-edgar","filing":"0000912282-24-000006","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091228224000006/form4.xml","form_type":"4"}},{"id":1766695,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27711,"kind":"person","name":"PYSZCZYMUKA GREG","position":1,"cik":"0001952920","reported_name":"PYSZCZYMUKA GREG","relationship":{"officer":true,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2023-10-03T20:37:00.000Z","date":"2023-09-30","kind":"exercise","planned":false,"acquired":false,"shares":208,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted on March 31, 2022, and vest as follows:  One-third on March 31, 2023; 1/12th of the original grant quarterly thereafter through March 31, 2025.  Settlement of vested RSUs will occur as soon as practicable following vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted on March 31, 2022, and vest as follows:  One-third on March 31, 2023; 1/12th of the original grant quarterly thereafter through March 31, 2025.  Settlement of vested RSUs will occur as soon as practicable following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted on March 31, 2022, and vest as follows:  One-third on March 31, 2023; 1/12th of the original grant quarterly thereafter through March 31, 2025.  Settlement of vested RSUs will occur as soon as practicable following vesting."}],"balance_after":1251,"derivative":{"underlying":"Common Shares","underlying_shares":208},"source":{"system":"sec-edgar","filing":"0000912282-23-000399","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091228223000399/form4.xml","form_type":"4"}},{"id":1766694,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27711,"kind":"person","name":"PYSZCZYMUKA GREG","position":1,"cik":"0001952920","reported_name":"PYSZCZYMUKA GREG","relationship":{"officer":true,"officer_title":"Chief Commercial Officer"}}],"security":"Common Shares","published_at":"2023-10-03T20:37:00.000Z","date":"2023-09-30","kind":"exercise","planned":false,"acquired":true,"shares":208,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted on March 31, 2022, and vest as follows:  One-third on March 31, 2023; 1/12th of the original grant quarterly thereafter through March 31, 2025.  Settlement of vested RSUs will occur as soon as practicable following vesting."}],"balance_after":22351,"source":{"system":"sec-edgar","filing":"0000912282-23-000399","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091228223000399/form4.xml","form_type":"4"}},{"id":1801661,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":22200,"kind":"person","name":"JAIN ABHINAV","position":1,"cik":"0001981291","reported_name":"JAIN ABHINAV","relationship":{"director":true}}],"security":"Common Shares","published_at":"2023-08-18T22:27:05.000Z","date":"2023-08-16","kind":"grant","planned":false,"acquired":true,"shares":6500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted shares, which vest as follows:  1/3 on June 14, 2024, with the remaining restricted shares vesting in eight equal installments every three months, beginning on September 14, 2024."}],"balance_after":8000,"source":{"system":"sec-edgar","filing":"0000912282-23-000317","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091228223000317/form4.xml","form_type":"4"}},{"id":1807069,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27710,"kind":"person","name":"Disbrow Jarrett","position":1,"cik":"0001640724","reported_name":"Disbrow Jarrett","relationship":{"officer":true,"officer_title":"Chief Business Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2023-08-16T00:57:06.000Z","date":"2023-08-11","kind":"grant","planned":false,"acquired":true,"shares":7000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest as follows:  1/3 on August 11, 2024, with the remaining options vesting in 24 equal monthly installments beginning September 11, 2024."}],"balance_after":7000,"derivative":{"exercise_price":1.73,"expiration_date":"2033-08-12","underlying":"Common Shares","underlying_shares":7000},"source":{"system":"sec-edgar","filing":"0000912282-23-000305","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091228223000305/form4.xml","form_type":"4"}},{"id":1807068,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":22200,"kind":"person","name":"JAIN ABHINAV","position":1,"cik":"0001981291","reported_name":"JAIN ABHINAV","relationship":{"director":true}}],"security":"Common Shares","published_at":"2023-08-15T23:49:08.000Z","date":"2023-08-11","kind":"grant","planned":false,"acquired":true,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted shares, which vest as follows:  1/3 on August 11, 2024, with the remaining restricted shares vesting in eight equal installments every three months, beginning on November 11, 2024."}],"balance_after":1500,"source":{"system":"sec-edgar","filing":"0000912282-23-000303","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091228223000303/form4.xml","form_type":"4"}},{"id":1807106,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27727,"kind":"person","name":"LIU VIVIAN H","position":1,"cik":"0001203467","reported_name":"LIU VIVIAN H","relationship":{"director":true}}],"security":"Common Shares","published_at":"2023-08-15T23:44:39.000Z","date":"2023-08-11","kind":"grant","planned":false,"acquired":true,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted shares, which vest as follows:  1/3 on August 11, 2024, with the remaining restricted shares vesting in eight equal installments every three months beginning on November 11, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects 1-for-20 reverse stock split effected by the Issuer on January 6, 2023."}],"balance_after":1841,"source":{"system":"sec-edgar","filing":"0000912282-23-000302","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1203467/000091228223000302/form4.xml","form_type":"4"}},{"id":1807067,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27708,"kind":"person","name":"Donofrio John Jr.","position":1,"cik":"0001679841","reported_name":"Donofrio John Jr.","relationship":{"director":true}}],"security":"Common Shares","published_at":"2023-08-15T23:39:52.000Z","date":"2023-08-11","kind":"grant","planned":false,"acquired":true,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted shares, which vest as follows:  1/3 on August 11, 2024, with the remaining restricted shares vesting in eight equal installments every three months beginning on November 11, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects 1-for-20 reverse stock split effected by the Issuer on January 6, 2023."}],"balance_after":2262,"source":{"system":"sec-edgar","filing":"0000912282-23-000301","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091228223000301/form4.xml","form_type":"4"}},{"id":1807066,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true}}],"security":"Common Shares","published_at":"2023-08-15T23:38:00.000Z","date":"2023-08-11","kind":"grant","planned":false,"acquired":true,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted shares, which vest as follows:  1/3 on August 11, 2024, with the remaining restricted shares vesting in eight equal installments every three months beginning on November 11, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects 1-for-20 reverse stock split effected by the Issuer on January 6, 2023."}],"balance_after":8940,"source":{"system":"sec-edgar","filing":"0000912282-23-000300","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091228223000300/form4.xml","form_type":"4"}},{"id":1807065,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27712,"kind":"person","name":"Disbrow Joshua R.","position":1,"cik":"0001566240","reported_name":"Disbrow Joshua R.","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2023-08-15T23:34:57.000Z","date":"2023-08-11","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest as follows:  1/3 on August 11, 2024, with the remaining options vesting in 24 equal monthly installments beginning September 11, 2024."}],"balance_after":35000,"derivative":{"exercise_price":1.73,"expiration_date":"2033-08-12","underlying":"Common Shares","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0000912282-23-000299","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091228223000299/form4.xml","form_type":"4"}},{"id":1807064,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":110535,"kind":"person","name":"BROOKE CHRISTOPHER","position":1,"cik":"0001953013","reported_name":"BROOKE CHRISTOPHER","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2023-08-15T23:30:20.000Z","date":"2023-08-11","kind":"grant","planned":false,"acquired":true,"shares":7000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest as follows: 1/3 vest on August 11, 2024, with the remaining options vesting in 24 equal monthly installments, beginning September 11, 2024."}],"balance_after":7000,"derivative":{"exercise_price":1.73,"expiration_date":"2033-08-12","underlying":"Common Shares","underlying_shares":7000},"source":{"system":"sec-edgar","filing":"0000912282-23-000297","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091228223000297/form4.xml","form_type":"4"}},{"id":1807063,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27711,"kind":"person","name":"PYSZCZYMUKA GREG","position":1,"cik":"0001952920","reported_name":"PYSZCZYMUKA GREG","relationship":{"officer":true,"officer_title":"Chief Commercial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2023-08-15T23:21:18.000Z","date":"2023-08-11","kind":"grant","planned":false,"acquired":true,"shares":7000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest as follows: 1/3 on August 11, 2024, with the remaining options vesting in 24 equal monthly installments beginning September 11, 2024."}],"balance_after":7000,"derivative":{"exercise_price":1.73,"expiration_date":"2033-08-12","underlying":"Common Shares","underlying_shares":7000},"source":{"system":"sec-edgar","filing":"0000912282-23-000295","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091228223000295/form4.xml","form_type":"4"}},{"id":1807311,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":68431,"kind":"person","name":"Oki Mark K","position":1,"cik":"0001491847","reported_name":"Oki Mark K","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2023-08-15T19:28:59.000Z","date":"2023-08-11","kind":"grant","planned":false,"acquired":true,"shares":13000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest as follows: 1/3 on August 11, 2024, with the remaining options vesting in 24 equal monthly installments beginning September 11, 2024."}],"balance_after":13000,"derivative":{"exercise_price":1.73,"expiration_date":"2033-08-12","underlying":"Common Shares","underlying_shares":13000},"source":{"system":"sec-edgar","filing":"0000912282-23-000296","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1491847/000091228223000296/form4.xml","form_type":"4"}},{"id":1833565,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27711,"kind":"person","name":"PYSZCZYMUKA GREG","position":1,"cik":"0001952920","reported_name":"PYSZCZYMUKA GREG","relationship":{"officer":true,"officer_title":"Chief Commerical Officer"}}],"security":"Restricted Stock Units","published_at":"2023-07-06T19:26:53.000Z","date":"2023-06-30","kind":"exercise","planned":false,"acquired":false,"shares":208,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted on March 31, 2022, and vest as follows:  One-third on March 31, 2023; 1/12th of the original grant quarterly thereafter through March 31, 2025.  Settlement of vested RSUs will occur as soon as practicable following vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted on March 31, 2022, and vest as follows:  One-third on March 31, 2023; 1/12th of the original grant quarterly thereafter through March 31, 2025.  Settlement of vested RSUs will occur as soon as practicable following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted on March 31, 2022, and vest as follows:  One-third on March 31, 2023; 1/12th of the original grant quarterly thereafter through March 31, 2025.  Settlement of vested RSUs will occur as soon as practicable following vesting."}],"balance_after":1459,"derivative":{"underlying":"Common Shares","underlying_shares":208},"source":{"system":"sec-edgar","filing":"0000912282-23-000164","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091228223000164/form4.xml","form_type":"4"}},{"id":1833564,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27711,"kind":"person","name":"PYSZCZYMUKA GREG","position":1,"cik":"0001952920","reported_name":"PYSZCZYMUKA GREG","relationship":{"officer":true,"officer_title":"Chief Commerical Officer"}}],"security":"Common Shares","published_at":"2023-07-06T19:26:53.000Z","date":"2023-06-30","kind":"exercise","planned":false,"acquired":true,"shares":208,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted on March 31, 2022, and vest as follows:  One-third on March 31, 2023; 1/12th of the original grant quarterly thereafter through March 31, 2025.  Settlement of vested RSUs will occur as soon as practicable following vesting."}],"balance_after":22143,"source":{"system":"sec-edgar","filing":"0000912282-23-000164","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091228223000164/form4.xml","form_type":"4"}},{"id":1849007,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27711,"kind":"person","name":"PYSZCZYMUKA GREG","position":1,"cik":"0001952920","reported_name":"PYSZCZYMUKA GREG","relationship":{"officer":true,"officer_title":"Chief Commerical Officer"}}],"security":"Common Shares","published_at":"2023-06-20T12:35:10.000Z","date":"2023-06-16","kind":"purchase","planned":false,"acquired":true,"shares":12000,"price":1.869,"value":22428.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The purchase price reported in Column 4 above is an average weighted price.  These shares were purchased in multiple transactions at prices ranging from $1.84 to $1.869, inclusive.  The reporting person undertakes to provide to AYTU Biopharma, Inc., any security holder of AYTU Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."}],"balance_after":21935,"source":{"system":"sec-edgar","filing":"0000912282-23-000137","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091228223000137/form4.xml","form_type":"4"}},{"id":1849009,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27711,"kind":"person","name":"PYSZCZYMUKA GREG","position":1,"cik":"0001952920","reported_name":"PYSZCZYMUKA GREG","relationship":{"officer":true,"officer_title":"Chief Commerical Officer"}}],"security":"Restricted Stock Units","published_at":"2023-06-20T12:29:12.000Z","date":"2023-04-25","kind":"exercise","planned":false,"acquired":false,"shares":833,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Represents restricted stock units (\"RSU\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted on March 31, 2022, and vest as follows:  One-third on March 31, 2023; 1/12th of the original grant quarterly thereafter through March 31, 2025.  Settlement of vested RSUs will occur as soon as practicable following vesting."},{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects a 1:20 reverse stock split effected by the Issuer on January 4, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents restricted stock units (\"RSU\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted on March 31, 2022, and vest as follows:  One-third on March 31, 2023; 1/12th of the original grant quarterly thereafter through March 31, 2025.  Settlement of vested RSUs will occur as soon as practicable following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Represents restricted stock units (\"RSU\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted on March 31, 2022, and vest as follows:  One-third on March 31, 2023; 1/12th of the original grant quarterly thereafter through March 31, 2025.  Settlement of vested RSUs will occur as soon as practicable following vesting."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Reflects a 1:20 reverse stock split effected by the Issuer on January 4, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Reflects a 1:20 reverse stock split effected by the Issuer on January 4, 2023."}],"balance_after":1667,"derivative":{"underlying":"Common Shares","underlying_shares":833},"source":{"system":"sec-edgar","filing":"0000912282-23-000135","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091228223000135/form4.xml","form_type":"4"}},{"id":1849008,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27711,"kind":"person","name":"PYSZCZYMUKA GREG","position":1,"cik":"0001952920","reported_name":"PYSZCZYMUKA GREG","relationship":{"officer":true,"officer_title":"Chief Commerical Officer"}}],"security":"Common Shares","published_at":"2023-06-20T12:29:12.000Z","date":"2023-04-25","kind":"exercise","planned":false,"acquired":true,"shares":833,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Reflects a 1:20 reverse stock split effected by the Issuer on January 4, 2023."}],"balance_after":9935,"source":{"system":"sec-edgar","filing":"0000912282-23-000135","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091228223000135/form4.xml","form_type":"4"}},{"id":1853986,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27712,"kind":"person","name":"Disbrow Joshua R.","position":1,"cik":"0001566240","reported_name":"Disbrow Joshua R.","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2023-06-15T17:52:53.000Z","date":"2023-06-14","kind":"purchase","planned":false,"acquired":true,"shares":14000,"price":1.8628,"value":26079.2,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The purchase price reported in Column 4 above is an average weighted price. These shares were purchased in multiple transactions at prices ranging from $1.79 to $1.87, inclusive. The reporting person undertakes to provide to AYTU Biopharma, Inc., any security holder of AYTU Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects a 1:20 reverse stock split effected by the Issuer on January 4, 2023."}],"balance_after":71591,"source":{"system":"sec-edgar","filing":"0000912282-23-000133","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091228223000133/form4.xml","form_type":"4"}},{"id":2022420,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27727,"kind":"person","name":"LIU VIVIAN H","position":1,"cik":"0001203467","reported_name":"LIU VIVIAN H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2023-02-10T23:13:33.000Z","date":"2023-02-08","kind":"grant","acquired":true,"shares":6500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted share grant.  One-third of the restricted shares shall vest on July 1, 2023; the remaining restricted shares shall vest quarterly thereafter, at 1/8th of the remaining grant, with full vesting on July 1, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Total reflects 1-to-20 reverse stock split effected by the Issuer on January 6, 2023."}],"balance_after":6825,"source":{"system":"sec-edgar","filing":"0001567619-23-002409","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1203467/000156761923002409/doc1.xml","form_type":"4"}},{"id":2076609,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27708,"kind":"person","name":"Donofrio John Jr.","position":1,"cik":"0001679841","reported_name":"Donofrio John Jr.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-23T22:40:12.000Z","date":"2022-12-21","kind":"disposition_to_issuer","acquired":false,"shares":187804,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On December 21, 2022, the reporting person and the Issuer determined to rescind 187,804 vested shares of restricted common stock originally granted to the reporting person on April 16, 2021. The vesting of the remaining restricted shares remains unchanged with 1/12 vesting on the first day of each quarterly anniversary of the grant, such that the restricted shares will be fully vested on the third anniversary of the grant, subject to the reporting person's continued service with the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 21, 2022, the reporting person and the Issuer determined to rescind 187,804 vested shares of restricted common stock originally granted to the reporting person on April 16, 2021. The vesting of the remaining restricted shares remains unchanged with 1/12 vesting on the first day of each quarterly anniversary of the grant, such that the restricted shares will be fully vested on the third anniversary of the grant, subject to the reporting person's continued service with the Issuer."}],"balance_after":15267,"source":{"system":"sec-edgar","filing":"0001567619-22-022004","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000156761922022004/doc1.xml","form_type":"4"}},{"id":2076608,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":121318,"kind":"person","name":"Cantrell Gary","position":1,"cik":"0001679246","reported_name":"Cantrell Gary","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-23T22:31:27.000Z","date":"2022-12-21","kind":"disposition_to_issuer","acquired":false,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On December 21, 2022, the reporting person and the Issuer determined to rescind 40,000 vested shares of restricted common stock originally granted to the reporting person on April 16, 2021.  The vesting of the remaining restricted shares remains unchanged with 1/12 vesting on the first day of each quarterly anniversary of the grant, such that the restricted shares will be fully vested on the third anniversary of the grant, subject to the reporting person's continued service with the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 21, 2022, the reporting person and the Issuer determined to rescind 40,000 vested shares of restricted common stock originally granted to the reporting person on April 16, 2021.  The vesting of the remaining restricted shares remains unchanged with 1/12 vesting on the first day of each quarterly anniversary of the grant, such that the restricted shares will be fully vested on the third anniversary of the grant, subject to the reporting person's continued service with the Issuer."}],"balance_after":164089,"source":{"system":"sec-edgar","filing":"0001567619-22-022001","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000156761922022001/doc1.xml","form_type":"4"}},{"id":2076618,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27712,"kind":"person","name":"Disbrow Joshua R.","position":1,"cik":"0001566240","reported_name":"Disbrow Joshua R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-12-23T22:27:26.000Z","date":"2022-12-20","kind":"disposition_to_issuer","acquired":false,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On December 21, 2022, the reporting person and the Issuer determined to rescind 80,000 vested shares of restricted common stock originally granted to the reporting person on April 16, 2021.  The vesting of the remaining restricted shares remains unchanged with 1/12 vesting on the first day of each quarterly anniversary of the grant, such that the restricted shares will be fully vested on the third anniversary of the grant, subject to the reporting person's continued service with the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 21, 2022, the reporting person and the Issuer determined to rescind 80,000 vested shares of restricted common stock originally granted to the reporting person on April 16, 2021.  The vesting of the remaining restricted shares remains unchanged with 1/12 vesting on the first day of each quarterly anniversary of the grant, such that the restricted shares will be fully vested on the third anniversary of the grant, subject to the reporting person's continued service with the Issuer."}],"balance_after":1151877,"source":{"system":"sec-edgar","filing":"0001567619-22-021999","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000156761922021999/doc1.xml","form_type":"4"}},{"id":2076619,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-23T22:13:05.000Z","date":"2022-12-21","kind":"disposition_to_issuer","acquired":false,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On December 21, 2022, the reporting person and the Issuer determined to rescind 40,000 vested shares of restricted common stock originally granted to the reporting person on April 16, 2021.  The vesting of the remaining restricted shares remains unchanged with 1/12 vesting on the first day of each quarterly anniversary of the grant, such that the restricted shares will be fully vested on the third anniversary of the grant, subject to the reporting person's continued service with the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 21, 2022, the reporting person and the Issuer determined to rescind 40,000 vested shares of restricted common stock originally granted to the reporting person on April 16, 2021.  The vesting of the remaining restricted shares remains unchanged with 1/12 vesting on the first day of each quarterly anniversary of the grant, such that the restricted shares will be fully vested on the third anniversary of the grant, subject to the reporting person's continued service with the Issuer."}],"balance_after":148805,"source":{"system":"sec-edgar","filing":"0001567619-22-021997","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000156761922021997/doc1.xml","form_type":"4"}},{"id":2078534,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27712,"kind":"person","name":"Disbrow Joshua R.","position":1,"cik":"0001566240","reported_name":"Disbrow Joshua R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-12-21T14:17:07.000Z","date":"2022-12-19","kind":"purchase","acquired":true,"shares":112371,"price":0.2229,"value":25047.4959,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The purchase price reported above is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.213 to $0.23, inclusive. The reporting person undertakes to provide to AYTU Biopharma, Inc., any security holder of AYTU Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."}],"balance_after":1231877,"source":{"system":"sec-edgar","filing":"0001567619-22-021900","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000156761922021900/doc1.xml","form_type":"4"}},{"id":2078533,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27711,"kind":"person","name":"PYSZCZYMUKA GREG","position":1,"cik":"0001952920","reported_name":"PYSZCZYMUKA GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-12-21T14:15:17.000Z","date":"2022-12-19","kind":"purchase","acquired":true,"shares":100000,"price":0.2448,"value":24480.0,"ownership":{"direct":true},"balance_after":182056,"source":{"system":"sec-edgar","filing":"0001567619-22-021899","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000156761922021899/doc1.xml","form_type":"4"}},{"id":2103191,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27712,"kind":"person","name":"Disbrow Joshua R.","position":1,"cik":"0001566240","reported_name":"Disbrow Joshua R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2022-11-28T21:30:31.000Z","date":"2022-11-18","kind":"purchase","acquired":true,"shares":222000,"price":0.237,"value":52614.0,"ownership":{"direct":true},"balance_after":1119506,"source":{"system":"sec-edgar","filing":"0001567619-22-020922","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000156761922020922/doc1.xml","form_type":"4/A","original_submission_date":"2022-11-21"}},{"id":2103336,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":68431,"kind":"person","name":"Oki Mark K","position":1,"cik":"0001491847","reported_name":"Oki Mark K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Shares","published_at":"2022-11-28T16:30:50.000Z","date":"2022-11-18","kind":"purchase","acquired":true,"shares":90000,"price":0.23,"value":20700.0,"ownership":{"direct":true},"balance_after":190000,"source":{"system":"sec-edgar","filing":"0001567619-22-020920","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1491847/000156761922020920/doc1.xml","form_type":"4/A","original_submission_date":"2022-11-21"}},{"id":2108263,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27712,"kind":"person","name":"Disbrow Joshua R.","position":1,"cik":"0001566240","reported_name":"Disbrow Joshua R.","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2022-11-21T14:30:25.000Z","date":"2022-11-18","kind":"grant","acquired":true,"shares":222000,"price":0.237,"value":52614.0,"ownership":{"direct":true},"balance_after":1119506,"source":{"system":"sec-edgar","filing":"0001654954-22-015599","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000165495422015599/section16.xml","form_type":"4"}},{"id":2108525,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":68431,"kind":"person","name":"Oki Mark K","position":1,"cik":"0001491847","reported_name":"Oki Mark K","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Shares","published_at":"2022-11-21T09:30:23.000Z","date":"2022-11-18","kind":"grant","acquired":true,"shares":90000,"price":0.23,"value":20700.0,"ownership":{"direct":true},"balance_after":190000,"source":{"system":"sec-edgar","filing":"0001654954-22-015598","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1491847/000165495422015598/section16.xml","form_type":"4"}},{"id":2216880,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27727,"kind":"person","name":"LIU VIVIAN H","position":1,"cik":"0001203467","reported_name":"LIU VIVIAN H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2022-07-01T19:12:37.000Z","date":"2022-07-01","kind":"grant","acquired":true,"shares":6500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represented restricted share grant.  One-third of the restricted shares shall vest on July 1, 2023; the remaining restricted shares shall vest quarterly thereafter, at 1/8th of the remaining grant, with full vesting on July 1, 2025."}],"balance_after":6500,"source":{"system":"sec-edgar","filing":"0001567619-22-013590","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1203467/000156761922013590/doc1.xml","form_type":"4"}},{"id":2432229,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":68431,"kind":"person","name":"Oki Mark K","position":1,"cik":"0001491847","reported_name":"Oki Mark K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Shares","published_at":"2022-01-19T11:42:33.000Z","date":"2022-01-17","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted share grant.  One-third of the restricted shares shall vest on January 17, 2023;  the remaining restricted shares shall vest quarterly thereafter, at 1/12th of the original grant, with full vesting on January 17, 2025."}],"balance_after":100000,"source":{"system":"sec-edgar","filing":"0001567619-22-001304","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1491847/000156761922001304/doc1.xml","form_type":"4"}},{"id":2720574,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-11T01:25:21.000Z","date":"2021-03-29","kind":"other","acquired":true,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote 1"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reported Shares were acquired by the Master Fund from the Issuer as a result of 300,000 non-transferable contingent value rights (collectively, the \"CVRs\") granted to the Master Fund as a former shareholder of Innovus Pharmaceuticals, Inc (\"Innovus\") upon consummation of the merger between the Issuer and Innovus on February 14, 2020.  The number of Shares received by the Master Fund pursuant to the CVRs was determined by the Issuer through the application of a formula based on the Issuer's achievement of certain revenue and profitability milestones."}],"balance_after":1342378,"source":{"system":"sec-edgar","filing":"0000919574-21-003313","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091957421003313/ownership.xml","form_type":"4"}},{"id":2720573,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-11T01:25:21.000Z","date":"2021-03-29","kind":"other","acquired":true,"shares":2085,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reported Shares were acquired by the Master Fund from the Issuer as a result of 300,000 non-transferable contingent value rights (collectively, the \"CVRs\") granted to the Master Fund as a former shareholder of Innovus Pharmaceuticals, Inc (\"Innovus\") upon consummation of the merger between the Issuer and Innovus on February 14, 2020.  The number of Shares received by the Master Fund pursuant to the CVRs was determined by the Issuer through the application of a formula based on the Issuer's achievement of certain revenue and profitability milestones."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported Shares were acquired by the Master Fund from the Issuer as a result of 300,000 non-transferable contingent value rights (collectively, the \"CVRs\") granted to the Master Fund as a former shareholder of Innovus Pharmaceuticals, Inc (\"Innovus\") upon consummation of the merger between the Issuer and Innovus on February 14, 2020.  The number of Shares received by the Master Fund pursuant to the CVRs was determined by the Issuer through the application of a formula based on the Issuer's achievement of certain revenue and profitability milestones."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported shares of common stock (the \"Shares\") of Aytu BioPharma, Inc. (the \"Issuer\") are directly held by Armistice s (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."}],"balance_after":1342378,"source":{"system":"sec-edgar","filing":"0000919574-21-003313","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091957421003313/ownership.xml","form_type":"4"}},{"id":2720572,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-11T01:25:21.000Z","date":"2021-03-20","kind":"other","acquired":true,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote 1"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reported Shares were acquired by the Master Fund from the Issuer as a result of 300,000 non-transferable contingent value rights (collectively, the \"CVRs\") granted to the Master Fund as a former shareholder of Innovus Pharmaceuticals, Inc (\"Innovus\") upon consummation of the merger between the Issuer and Innovus on February 14, 2020.  The number of Shares received by the Master Fund pursuant to the CVRs was determined by the Issuer through the application of a formula based on the Issuer's achievement of certain revenue and profitability milestones."}],"balance_after":1340293,"source":{"system":"sec-edgar","filing":"0000919574-21-003313","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091957421003313/ownership.xml","form_type":"4"}},{"id":2720571,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-11T01:25:21.000Z","date":"2021-03-20","kind":"other","acquired":true,"shares":6959,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reported Shares were acquired by the Master Fund from the Issuer as a result of 300,000 non-transferable contingent value rights (collectively, the \"CVRs\") granted to the Master Fund as a former shareholder of Innovus Pharmaceuticals, Inc (\"Innovus\") upon consummation of the merger between the Issuer and Innovus on February 14, 2020.  The number of Shares received by the Master Fund pursuant to the CVRs was determined by the Issuer through the application of a formula based on the Issuer's achievement of certain revenue and profitability milestones."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported Shares were acquired by the Master Fund from the Issuer as a result of 300,000 non-transferable contingent value rights (collectively, the \"CVRs\") granted to the Master Fund as a former shareholder of Innovus Pharmaceuticals, Inc (\"Innovus\") upon consummation of the merger between the Issuer and Innovus on February 14, 2020.  The number of Shares received by the Master Fund pursuant to the CVRs was determined by the Issuer through the application of a formula based on the Issuer's achievement of certain revenue and profitability milestones."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported shares of common stock (the \"Shares\") of Aytu BioPharma, Inc. (the \"Issuer\") are directly held by Armistice s (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."}],"balance_after":1340293,"source":{"system":"sec-edgar","filing":"0000919574-21-003313","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091957421003313/ownership.xml","form_type":"4"}},{"id":2746697,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-16T21:26:30.000Z","date":"2021-04-16","kind":"grant","acquired":true,"shares":187804,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted shares. The restricted shares have the following accelerated vesting conditions: (1) The consummation of a Sale Event. (2) The closing price of the Company's stock price is equal or greater than forty dollars per share ($40) for two consecutive trading days. (3) The Grantee's service with the Company or a Related Entity is terminated by the Company without Cause (as defined below). The restricted shares vest as follows, and have no voting or dispositive rights until vested:  1/3 on April 16, 2022, and 1/12 on the first day of each quarter thereafter, such that the restricted shares will be fully vested on the third anniversary of the grant, subject to the reporting person's continuing employment with the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Grant of restricted shares. The restricted shares have the following accelerated vesting conditions: (1) The consummation of a Sale Event. (2) The closing price of the Company's stock price is equal or greater than forty dollars per share ($40) for two consecutive trading days. (3) The Grantee's service with the Company or a Related Entity is terminated by the Company without Cause (as defined below). The restricted shares vest as follows, and have no voting or dispositive rights until vested:  1/3 on April 16, 2022, and 1/12 on the first day of each quarter thereafter, such that the restricted shares will be fully vested on the third anniversary of the grant, subject to the reporting person's continuing employment with the Issuer."}],"balance_after":188805,"source":{"system":"sec-edgar","filing":"0001567619-21-008238","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000156761921008238/doc1.xml","form_type":"4"}},{"id":2746696,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27708,"kind":"person","name":"Donofrio John Jr.","position":1,"cik":"0001679841","reported_name":"Donofrio John Jr.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-16T20:53:15.000Z","date":"2021-04-16","kind":"grant","acquired":true,"shares":187804,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted shares. The restricted shares have the following accelerated vesting conditions: (1) The consummation of a Sale Event. (2) The closing price of the Company's stock price is equal or greater than forty dollars per share ($40) for two consecutive trading days. (3) The Grantee's service with the Company or a Related Entity is terminated by the Company without Cause (as defined below). The restricted shares vest as follows, and have no voting or dispositive rights until vested:  1/3 on April 16, 2022, and 1/12 on the first day of each quarter thereafter, such that the restricted shares will be fully vested on the third anniversary of the grant, subject to the reporting person's continuing employment with the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Grant of restricted shares. The restricted shares have the following accelerated vesting conditions: (1) The consummation of a Sale Event. (2) The closing price of the Company's stock price is equal or greater than forty dollars per share ($40) for two consecutive trading days. (3) The Grantee's service with the Company or a Related Entity is terminated by the Company without Cause (as defined below). The restricted shares vest as follows, and have no voting or dispositive rights until vested:  1/3 on April 16, 2022, and 1/12 on the first day of each quarter thereafter, such that the restricted shares will be fully vested on the third anniversary of the grant, subject to the reporting person's continuing employment with the Issuer."}],"balance_after":203071,"source":{"system":"sec-edgar","filing":"0001567619-21-008230","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000156761921008230/doc1.xml","form_type":"4"}},{"id":2746695,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":121318,"kind":"person","name":"Cantrell Gary","position":1,"cik":"0001679246","reported_name":"Cantrell Gary","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-16T20:51:42.000Z","date":"2021-04-16","kind":"grant","acquired":true,"shares":187804,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted shares. The restricted shares have the following accelerated vesting conditions: (1) The consummation of a Sale Event. (2) The closing price of the Company's stock price is equal or greater than forty dollars per share ($40) for two consecutive trading days. (3) The Grantee's service with the Company or a Related Entity is terminated by the Company without Cause (as defined below). The restricted shares vest as follows, and have no voting or dispositive rights until vested:  1/3 on April 16, 2022, and 1/12 on the first day of each quarter thereafter, such that the restricted shares will be fully vested on the third anniversary of the grant, subject to the reporting person's continuing employment with the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Grant of restricted shares. The restricted shares have the following accelerated vesting conditions: (1) The consummation of a Sale Event. (2) The closing price of the Company's stock price is equal or greater than forty dollars per share ($40) for two consecutive trading days. (3) The Grantee's service with the Company or a Related Entity is terminated by the Company without Cause (as defined below). The restricted shares vest as follows, and have no voting or dispositive rights until vested:  1/3 on April 16, 2022, and 1/12 on the first day of each quarter thereafter, such that the restricted shares will be fully vested on the third anniversary of the grant, subject to the reporting person's continuing employment with the Issuer."}],"balance_after":204089,"source":{"system":"sec-edgar","filing":"0001567619-21-008229","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000156761921008229/doc1.xml","form_type":"4"}},{"id":2746694,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27712,"kind":"person","name":"Disbrow Joshua R.","position":1,"cik":"0001566240","reported_name":"Disbrow Joshua R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-04-16T20:49:57.000Z","date":"2021-04-16","kind":"grant","acquired":true,"shares":800000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted shares. The restricted shares have the following accelerated vesting conditions: (1) The consummation of a Sale Event. (2) The closing price of the Company's stock price is equal or greater than forty dollars per share ($40) for two consecutive trading days. (3) The Grantee's service with the Company or a Related Entity is terminated by the Company without Cause (as defined below). (4) At the Compensation Committee's discretion based on the Company achieving certain revenue milestones and the successful integration of future acquisitions. The restricted shares vest as follows, and have no voting or dispositive rights until vested:  1/3 on April 16, 2022, and 1/12 on the first day of each quarter thereafter, such that the restricted shares will be fully vested on the third anniversary of the grant, subject to the reporting person's continuing employment with the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Grant of restricted shares. The restricted shares have the following accelerated vesting conditions: (1) The consummation of a Sale Event. (2) The closing price of the Company's stock price is equal or greater than forty dollars per share ($40) for two consecutive trading days. (3) The Grantee's service with the Company or a Related Entity is terminated by the Company without Cause (as defined below). (4) At the Compensation Committee's discretion based on the Company achieving certain revenue milestones and the successful integration of future acquisitions. The restricted shares vest as follows, and have no voting or dispositive rights until vested:  1/3 on April 16, 2022, and 1/12 on the first day of each quarter thereafter, such that the restricted shares will be fully vested on the third anniversary of the grant, subject to the reporting person's continuing employment with the Issuer."}],"balance_after":897506,"source":{"system":"sec-edgar","filing":"0001567619-21-008228","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000156761921008228/doc1.xml","form_type":"4"}},{"id":2747608,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":131757,"kind":"person","name":"MACALUSO MICHAEL","position":1,"cik":"0001096423","reported_name":"MACALUSO MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-16T16:55:50.000Z","date":"2021-04-16","kind":"grant","acquired":true,"shares":187804,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted shares. The restricted shares have the following accelerated vesting conditions: (1) The consummation of a Sale Event. (2) The closing price of the Company's stock price is equal or greater than forty dollars per share ($40) for two consecutive trading days. (3) The Grantee's service with the Company or a Related Entity is terminated by the Company without Cause (as defined below).The restricted shares vest as follows, and have no voting or dispositive rights until vested:  1/3 on April 16, 2022, and 1/12 on the first day of each quarter thereafter, such that the restricted shares will be fully vested on the third anniversary of the grant, subject to the reporting person's continuing employment with the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Grant of restricted shares. The restricted shares have the following accelerated vesting conditions: (1) The consummation of a Sale Event. (2) The closing price of the Company's stock price is equal or greater than forty dollars per share ($40) for two consecutive trading days. (3) The Grantee's service with the Company or a Related Entity is terminated by the Company without Cause (as defined below).The restricted shares vest as follows, and have no voting or dispositive rights until vested:  1/3 on April 16, 2022, and 1/12 on the first day of each quarter thereafter, such that the restricted shares will be fully vested on the third anniversary of the grant, subject to the reporting person's continuing employment with the Issuer."}],"balance_after":208079,"source":{"system":"sec-edgar","filing":"0001567619-21-008232","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1096423/000156761921008232/doc1.xml","form_type":"4"}},{"id":2751192,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":49124,"kind":"person","name":"McLaughlin Gerald W.","position":1,"cik":"0001495412","reported_name":"McLaughlin Gerald W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-12T20:39:26.000Z","date":"2021-04-08","kind":"grant","acquired":true,"shares":6500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of AYTU common stock. The RSUs have the following accelerated vesting conditions: (1) The consummation of a Sale Event. (2) The closing price of the Company's stock price is equal or greater than forty dollars per share ($40) for two consecutive trading days. (3) The Grantee's service with the Company or a Related Entity is terminated by the Company without Cause (as defined below).The RSUs vest as follows, and have no voting or dispositive rights until vested: one year vest from date of grant, April 8, 2021 such that the RSUs will be fully vested on April 8, 2022, subject to the reporting person's continuing employment with the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Grant of restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of AYTU common stock. The RSUs have the following accelerated vesting conditions: (1) The consummation of a Sale Event. (2) The closing price of the Company's stock price is equal or greater than forty dollars per share ($40) for two consecutive trading days. (3) The Grantee's service with the Company or a Related Entity is terminated by the Company without Cause (as defined below).The RSUs vest as follows, and have no voting or dispositive rights until vested: one year vest from date of grant, April 8, 2021 such that the RSUs will be fully vested on April 8, 2022, subject to the reporting person's continuing employment with the Issuer."}],"balance_after":31401,"source":{"system":"sec-edgar","filing":"0001567619-21-007912","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1495412/000156761921007912/doc1.xml","form_type":"4"}},{"id":2751102,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":17834,"kind":"person","name":"Hecht Beth","position":1,"cik":"0001652410","reported_name":"Hecht Beth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-12T19:22:04.000Z","date":"2021-04-08","kind":"grant","acquired":true,"shares":6500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of AYTU common stock. The RSUs have the following accelerated vesting conditions: (1) The consummation of a Sale Event. (2) The closing price of the Company's stock price is equal or greater than forty dollars per share ($40) for two consecutive trading days. (3) The Grantee's service with the Company or a Related Entity is terminated by the Company without Cause (as defined below).The RSUs vest as follows, and have no voting or dispositive rights until vested: one year vest from date of grant, April 8, 2021 such that the RSUs will be fully vested on April 8, 2022, subject to the reporting person's continuing employment with the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Grant of restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of AYTU common stock. The RSUs have the following accelerated vesting conditions: (1) The consummation of a Sale Event. (2) The closing price of the Company's stock price is equal or greater than forty dollars per share ($40) for two consecutive trading days. (3) The Grantee's service with the Company or a Related Entity is terminated by the Company without Cause (as defined below).The RSUs vest as follows, and have no voting or dispositive rights until vested: one year vest from date of grant, April 8, 2021 such that the RSUs will be fully vested on April 8, 2022, subject to the reporting person's continuing employment with the Issuer."}],"balance_after":9052,"source":{"system":"sec-edgar","filing":"0001567619-21-007909","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000156761921007909/doc1.xml","form_type":"4"}},{"id":2757087,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":94716,"kind":"person","name":"Eisenstadt Richard I","position":1,"cik":"0001515806","reported_name":"Eisenstadt Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Shares","published_at":"2021-04-05T23:15:11.000Z","date":"2021-03-31","kind":"grant","acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Grant of restricted stock units (\"RSUs\").  Each RSU represents a contingent right to receive one share of AYTU common stock.  The RSUs vest as follows, and have no voting or dispositive rights until vested:  1/3 on April 1, 2022, and 1/12 on the first day of each quarter thereafter, such that the RSUs will be fully vested on the third anniversary of the grant, subject to the reporting person's continuing employment with the Issuer."},{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted stock units (\"RSUs\").  Each RSU represents a contingent right to receive one share of AYTU common stock.  The RSUs vest as follows, and have no voting or dispositive rights until vested:  1/3 on April 1, 2022, and 1/12 on the first day of each quarter thereafter, such that the RSUs will be fully vested on the third anniversary of the grant, subject to the reporting person's continuing employment with the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Grant of restricted stock units (\"RSUs\").  Each RSU represents a contingent right to receive one share of AYTU common stock.  The RSUs vest as follows, and have no voting or dispositive rights until vested:  1/3 on April 1, 2022, and 1/12 on the first day of each quarter thereafter, such that the RSUs will be fully vested on the third anniversary of the grant, subject to the reporting person's continuing employment with the Issuer."}],"balance_after":68734,"source":{"system":"sec-edgar","filing":"0001567619-21-007654","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000156761921007654/doc1.xml","form_type":"4"}},{"id":2944092,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-16T00:17:57.000Z","date":"2020-12-11","kind":"purchase","acquired":true,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote 1"},"balance_after":1333334,"source":{"system":"sec-edgar","filing":"0000919574-20-007541","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091957420007541/ownership.xml","form_type":"4"}},{"id":2944091,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-16T00:17:57.000Z","date":"2020-12-11","kind":"purchase","acquired":true,"shares":1333334,"price":6,"value":8000004.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported securities of Aytu BioScience, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital. Armistice Capital and Steven Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":1333334,"source":{"system":"sec-edgar","filing":"0000919574-20-007541","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091957420007541/ownership.xml","form_type":"4"}},{"id":3055549,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true}}],"security":"Employee Stock Option Grant","published_at":"2020-08-17T16:29:47.000Z","date":"2020-06-08","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"100% vest on June 7, 2021, subject to the Grantee's continued service as a director on such dates."}],"balance_after":40038,"derivative":{"exercise_price":1.45,"expiration_date":"2030-06-07","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001654954-20-009234","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000165495420009234/section16.xml","form_type":"4"}},{"id":3111496,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27708,"kind":"person","name":"Donofrio John Jr.","position":1,"cik":"0001679841","reported_name":"Donofrio John Jr.","relationship":{"director":true}}],"security":"Employee Stock Option Grant","published_at":"2020-06-12T21:45:39.000Z","date":"2020-06-08","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"100% vest on June 7, 2021, subject to the Grantee's continued service as a director on such dates."}],"balance_after":40038,"derivative":{"exercise_price":1.45,"expiration_date":"2030-06-07","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001654954-20-006584","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000165495420006584/section16.xml","form_type":"4"}},{"id":3111498,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27712,"kind":"person","name":"Disbrow Joshua R.","position":1,"cik":"0001566240","reported_name":"Disbrow Joshua R.","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option Grant","published_at":"2020-06-12T21:44:15.000Z","date":"2020-06-08","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"2.\t25% vests on June 7, 2021, with an additional 6.25% of the total shares vesting quarterly thereafter, subject to continued service through each vesting date until June 7, 2024."}],"balance_after":100275,"derivative":{"exercise_price":1.45,"expiration_date":"2030-06-07","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001654954-20-006583","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000165495420006583/section16.xml","form_type":"4"}},{"id":3111497,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27712,"kind":"person","name":"Disbrow Joshua R.","position":1,"cik":"0001566240","reported_name":"Disbrow Joshua R.","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2020-06-12T21:44:15.000Z","date":"2020-06-08","kind":"grant","acquired":true,"shares":450000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"1.\tThese are restricted shares. 25% vests on June 7, 2021, with an additional 6.25% of the total shares vesting quarterly thereafter, subject to continued service through each vesting date until June 7, 2024"}],"balance_after":975048,"source":{"system":"sec-edgar","filing":"0001654954-20-006583","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000165495420006583/section16.xml","form_type":"4"}},{"id":3111495,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":121318,"kind":"person","name":"Cantrell Gary","position":1,"cik":"0001679246","reported_name":"Cantrell Gary","relationship":{"director":true}}],"security":"Employee Stock Option Grant","published_at":"2020-06-12T21:42:33.000Z","date":"2020-06-08","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"100% vest on June 7, 2021, subject to the Grantee's continued service as a director on such dates."}],"balance_after":20038,"derivative":{"exercise_price":1.45,"expiration_date":"2030-06-07","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001654954-20-006582","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000165495420006582/section16.xml","form_type":"4"}}],"next_cursor":"2020-06-12T21:42:33.000000Z,3111495"}